Symbols

ESLA

Estrella·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

Consensus Rating "Strong Buy"

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ESLA

Estrella Immunopharma, Inc.

A preclinical-stage biopharmaceutical company developing T-cell therapies

Industry

Biological Technology

Established Date

03/30/2022

Listing Date

09/14/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.estrellabio.com

Security Type

Common stock

Office address

5858 Horton Street, Suite 370, Emeryville, California 94608

Business

Introduction

Estrella Immunopharma, Inc., was incorporated in Delaware on March 30, 2022. The Company is a clinical-stage biopharmaceutical company utilizing its proprietary ARTEMIS technology to develop T-cell therapies for hematological cancers and solid tumors. Its main drug candidate EB103 targets CD19 for the treatment of B-cell malignancies, while a dual-targeted drug candidate EB104 is also being developed.

Company Financials

EPS

ESLA has released its 2025 Q2 earnings. EPS was reported at -0.15, versus the expected -0.11, missing expectations. The chart below visualizes how ESLA has performed over recent quarters, highlighting trends in earnings surprises.